Latest News and Press Releases

MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from...

MONTRÉAL, 06 mai 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui les...

MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on...

MONTRÉAL, 30 avr. 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (ex. EU), publiera ses résultats financiers du premier...

– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026 ...

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...

MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President...

MONTRÉAL, 15 avr. 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente...

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13,...

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent,...